Join
Live feed
·
PRReleasevia Quantisnow
Krystal Biotech Inc. logo

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

ByQuantisnow·Wall Street's wire, on your screen.
KRYS· Krystal Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KRYS (Krystal Biotech Inc.) and more on Quantisnow.